Exchange Traded Concepts LLC Grows Stock Holdings in Illumina, Inc. $ILMN

Exchange Traded Concepts LLC raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 225,029 shares of the life sciences company’s stock after purchasing an additional 4,338 shares during the period. Exchange Traded Concepts LLC owned approximately 0.14% of Illumina worth $21,470,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Fourth Dimension Wealth LLC purchased a new stake in Illumina during the fourth quarter valued at about $40,000. Rise Advisors LLC raised its position in Illumina by 173.6% during the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 224 shares in the last quarter. Rakuten Securities Inc. raised its position in Illumina by 290.3% during the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock valued at $29,000 after purchasing an additional 270 shares in the last quarter. Center for Financial Planning Inc. bought a new position in shares of Illumina during the first quarter valued at about $33,000. Finally, PFS Partners LLC grew its stake in shares of Illumina by 400.0% during the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company’s stock valued at $40,000 after buying an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of recent research reports. Wall Street Zen cut Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Daiwa Capital Markets cut Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price objective on the stock. in a research note on Tuesday, August 12th. Canaccord Genuity Group raised their price objective on Illumina from $99.00 to $105.00 and gave the company a “hold” rating in a research note on Friday, August 1st. Royal Bank Of Canada set a $124.00 price objective on Illumina in a research note on Tuesday, September 2nd. Finally, Daiwa America cut Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $123.06.

Illumina Stock Performance

ILMN stock opened at $100.87 on Thursday. The stock has a market capitalization of $15.50 billion, a PE ratio of 12.77, a price-to-earnings-growth ratio of 2.28 and a beta of 1.43. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The stock’s 50 day simple moving average is $99.65 and its 200 day simple moving average is $88.78.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. The business had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company’s quarterly revenue was down 4.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.